180 related articles for article (PubMed ID: 18174247)
1. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
2. The transglutaminase 2 gene is aberrantly hypermethylated in glioma.
Dyer LM; Schooler KP; Ai L; Klop C; Qiu J; Robertson KD; Brown KD
J Neurooncol; 2011 Feb; 101(3):429-40. PubMed ID: 20596752
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
Ai L; Tao Q; Zhong S; Fields CR; Kim WJ; Lee MW; Cui Y; Brown KD; Robertson KD
Carcinogenesis; 2006 Jul; 27(7):1341-8. PubMed ID: 16501252
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE
Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 silencing reduced the beta-amyloid-effects on the activation of human THP-1 cells.
Currò M; Ferlazzo N; Condello S; Caccamo D; Ientile R
Amino Acids; 2010 Nov; 39(5):1427-33. PubMed ID: 20437185
[TBL] [Abstract][Full Text] [Related]
11. [Epigenetic inactivation of microRNA genes in mammary carcinoma].
Lehmann U; Hasemeier B; Römermann D; Müller M; Länger F; Kreipe H
Verh Dtsch Ges Pathol; 2007; 91():214-20. PubMed ID: 18314617
[TBL] [Abstract][Full Text] [Related]
12. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.
Villar-Garea A; Fraga MF; Espada J; Esteller M
Cancer Res; 2003 Aug; 63(16):4984-9. PubMed ID: 12941824
[TBL] [Abstract][Full Text] [Related]
13. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer.
Miyoshi N; Ishii H; Mimori K; Tanaka F; Hitora T; Tei M; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2010 Apr; 17(4):967-72. PubMed ID: 20033322
[TBL] [Abstract][Full Text] [Related]
14. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
Toyota M; Suzuki H; Sasaki Y; Maruyama R; Imai K; Shinomura Y; Tokino T
Cancer Res; 2008 Jun; 68(11):4123-32. PubMed ID: 18519671
[TBL] [Abstract][Full Text] [Related]
16. ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2.
Jandrig B; Seitz S; Hinzmann B; Arnold W; Micheel B; Koelble K; Siebert R; Schwartz A; Ruecker K; Schlag PM; Scherneck S; Rosenthal A
Oncogene; 2004 Dec; 23(57):9295-302. PubMed ID: 15489893
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion.
Kim M; Jang HR; Kim JH; Noh SM; Song KS; Cho JS; Jeong HY; Norman JC; Caswell PT; Kang GH; Kim SY; Yoo HS; Kim YS
Carcinogenesis; 2008 Mar; 29(3):629-37. PubMed ID: 18283041
[TBL] [Abstract][Full Text] [Related]
18. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
19. Frequent epigenetic inactivation of cystatin M in breast carcinoma.
Schagdarsurengin U; Pfeifer GP; Dammann R
Oncogene; 2007 May; 26(21):3089-94. PubMed ID: 17099723
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer.
Hu XT; Zhang FB; Fan YC; Shu XS; Wong AH; Zhou W; Shi QL; Tang HM; Fu L; Guan XY; Rha SY; Tao Q; He C
Oncogene; 2009 Jul; 28(26):2466-75. PubMed ID: 19448674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
